EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Pharmacologic targeting of eEF2K in cardiovascular diseases: Mechanisms and potential clinical applications

Aysa Rezabakhsh, Solomon Habtemariam, Elnaz Khani, Batool Ghorbani Yekta, Raha Rahmani, Hadis Iraji, Seyed Mohammad Nabavi

European Journal of Pharmacology · 2025

DOI: 10.1016/j.ejphar.2025.178253 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Pharmacology, 2025. Verfasst von Aysa Rezabakhsh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: rezabakhsha@tbzmed.ac.ir. Hauptthemen laut MEDLINE: Elongation Factor 2 Kinase, Cardiovascular Diseases, Protein Kinase Inhibitors. Die Arbeit nennt 102 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Eukaryotic elongation factor 2 kinase (eEF2K) is a calcium/calmodulin-dependent enzyme that regulates protein synthesis by phosphorylating eukaryotic elongation factor 2 (eEF2). Activation of eEF2K under stress conditions such as nutrient deprivation, hypoxia, and oxidative stress helps conserve cellular energy and supports cell survival. Although eEF2K has been extensively studied in cancer and neurodegenerative diseases, increasing evidence emphasizes its crucial role in cardiovascular diseases (CVD), including hypertension, pulmonary arterial hypertension (PAH), ischemia/reperfusion injury, and atherosclerosis. This review outlines the structural and regulatory features of eEF2K and examines how its modulation affects cardiomyocyte survival, autophagy, mitochondrial quality control, and endothelial function. Additionally, preclinical studies indicate that pharmacological inhibition of eEF2K can enhance vascular remodeling, improve hemodynamics, and promote endothelial function. Conversely, activating eEF2K may offer protection against ischemic injury through enhanced autophagy and metabolic adaptation. Additionally, controlling sirtuin (SIRT), 5'-adenosine monophosphate (AMP)-activated protein kinase (AMPK), mechanistic target of rapamycin complex-1 (mTORC1), and autophagy/mitophagy flux via eEF2K modulation could help safeguard cardiomyocytes and endothelial cells from ischemic damage. These findings underscore the dual, context-dependent roles of eEF2K in CVD. We also review emerging small-molecule inhibitors, natural compounds, and innovative strategies, such as eEF2K degraders, highlighting their therapeutic potential and the challenges associated with clinical translation. Main limitations include issues of selectivity, potential toxicity, and the absence of validated biomarkers for patient stratification and treatment monitoring. Overall, targeting eEF2K offers a promising and complex strategy for CVD treatment. Further research into selective modulators, biomarker development, and clinical trials is essential to translate preclinical results into effective therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Elongation Factor 2 KinaseCardiovascular DiseasesProtein Kinase InhibitorsHumansAnimalsMolecular Targeted TherapyAutophagyMyocytes, Cardiac

Stichwörter der Autor:innen

AutophagyCardiovascular diseaseEukaryotic elongation factor 2 kinase (eEF2K)Pharmacologic target

Substanzen

Elongation Factor 2 KinaseEEF2K protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: rezabakhsha@tbzmed.ac.ir.
  • Pharmacognosy Research & Herbal Analysis Services UK, 124 City Road, London, EC1V 2NX, UK.
  • Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Department of Physiology, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran…
  • Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Advanced Medical Pharma (AMP-Biotec), Biopharmaceutical Innovation Centre, Via Cortenocera, 82030, San Salvatore Telesino, (BN), Italy; Nutringredientes Research Center, Federal Institute of Education, Science and Techn…

Zitieren

APA

Rezabakhsh, A., Habtemariam, S., Khani, E., Ghorbani Yekta, B., Rahmani, R., Iraji, H., & Nabavi, S. M. (2025). Pharmacologic targeting of eEF2K in cardiovascular diseases: Mechanisms and potential clinical applications. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2025.178253

Vancouver

Rezabakhsh A, Habtemariam S, Khani E, Ghorbani Yekta B, Rahmani R, Iraji H, et al. Pharmacologic targeting of eEF2K in cardiovascular diseases: Mechanisms and potential clinical applications. European Journal of Pharmacology. 2025. doi:10.1016/j.ejphar.2025.178253

BibTeX
@article{Rezabakhsh2025,
  author = {Rezabakhsh, Aysa and Habtemariam, Solomon and Khani, Elnaz and Ghorbani Yekta, Batool and Rahmani, Raha and Iraji, Hadis and Nabavi, Seyed Mohammad},
  title = {Pharmacologic targeting of eEF2K in cardiovascular diseases: Mechanisms and potential clinical applications},
  journal = {European Journal of Pharmacology},
  year = {2025},
  doi = {10.1016/j.ejphar.2025.178253}
}
Kostenlos starten →